CA2526082C - Triazole-derivatives as factor xa inhibitors - Google Patents

Triazole-derivatives as factor xa inhibitors Download PDF

Info

Publication number
CA2526082C
CA2526082C CA2526082A CA2526082A CA2526082C CA 2526082 C CA2526082 C CA 2526082C CA 2526082 A CA2526082 A CA 2526082A CA 2526082 A CA2526082 A CA 2526082A CA 2526082 C CA2526082 C CA 2526082C
Authority
CA
Canada
Prior art keywords
alkyl
another
unsubstituted
alkylene
mono
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2526082A
Other languages
English (en)
French (fr)
Other versions
CA2526082A1 (en
Inventor
Marc Nazare
Volker Laux
Armin Bauer
Michael Wagner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis Deutschland GmbH
Original Assignee
Sanofi Aventis Deutschland GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis Deutschland GmbH filed Critical Sanofi Aventis Deutschland GmbH
Publication of CA2526082A1 publication Critical patent/CA2526082A1/en
Application granted granted Critical
Publication of CA2526082C publication Critical patent/CA2526082C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA2526082A 2003-05-19 2004-05-05 Triazole-derivatives as factor xa inhibitors Expired - Fee Related CA2526082C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP03011309.6 2003-05-19
EP03011309A EP1479679A1 (en) 2003-05-19 2003-05-19 Triazole-derivatives as factor Xa inhibitors
PCT/EP2004/004752 WO2004101555A1 (en) 2003-05-19 2004-05-05 TRIAZOLE-DERIVATIVES AS FACTOR Xa INHIBITORS

Publications (2)

Publication Number Publication Date
CA2526082A1 CA2526082A1 (en) 2004-11-25
CA2526082C true CA2526082C (en) 2012-07-24

Family

ID=33040956

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2526082A Expired - Fee Related CA2526082C (en) 2003-05-19 2004-05-05 Triazole-derivatives as factor xa inhibitors

Country Status (12)

Country Link
EP (2) EP1479679A1 (enExample)
JP (1) JP4608495B2 (enExample)
AT (1) ATE394396T1 (enExample)
AU (1) AU2004238498B2 (enExample)
BR (1) BRPI0410763A (enExample)
CA (1) CA2526082C (enExample)
DE (1) DE602004013577D1 (enExample)
IL (1) IL171843A (enExample)
MX (1) MXPA05012058A (enExample)
PE (1) PE20050154A1 (enExample)
TW (1) TW200503694A (enExample)
WO (1) WO2004101555A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7453002B2 (en) 2004-06-15 2008-11-18 Bristol-Myers Squibb Company Five-membered heterocycles useful as serine protease inhibitors
KR101362024B1 (ko) * 2006-03-24 2014-02-11 에자이 알앤드디 매니지먼트 가부시키가이샤 트리아졸론 유도체
SG187396A1 (en) * 2007-07-19 2013-02-28 Lundbeck & Co As H 5-membered heterocyclic amides and related compounds
US7807690B2 (en) 2007-09-21 2010-10-05 Eisai R&D Management Co., Ltd. 2,3-dihydro-iminoisoindole derivatives
RU2017144535A (ru) 2010-03-30 2019-02-18 Версеон Корпорейшн Мультизамещенные ароматические соединения в качестве ингибиторов тромбина
BR112015023214A8 (pt) * 2013-03-15 2019-12-24 Verseon Corp composto, composição farmacêutica, e, uso de um composto ou composição farmacêutica
PL2968297T3 (pl) 2013-03-15 2019-04-30 Verseon Corp Wielopodstawione związki aromatyczne jako inhibitory protezy serynowej
CA2907111C (en) 2013-03-15 2023-10-24 Joel Moore Sgc stimulators
EP3194369A4 (en) 2014-09-17 2018-02-28 Verseon Corporation Pyrazolyl-substituted pyridone compounds as serine protease inhibitors
CA2977993A1 (en) 2015-02-27 2016-09-01 Verseon Corporation Substituted pyrazole compounds as serine protease inhibitors
US11724997B2 (en) 2018-03-01 2023-08-15 Annapurna Bio, Inc. Compounds and compositions for treating conditions associated with APJ receptor activity

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6020357A (en) * 1996-12-23 2000-02-01 Dupont Pharmaceuticals Company Nitrogen containing heteroaromatics as factor Xa inhibitors
US5998424A (en) * 1997-06-19 1999-12-07 Dupont Pharmaceuticals Company Inhibitors of factor Xa with a neutral P1 specificity group
US6339099B1 (en) * 1997-06-20 2002-01-15 Dupont Pharmaceuticals Company Guanidine mimics as factor Xa inhibitors
CA2314401A1 (en) * 1997-12-22 1999-07-01 Du Pont Pharmaceuticals Company Nitrogen containing heteroaromatics with ortho-substituted p1's as factor xa inhibitors
US6632815B2 (en) * 1999-09-17 2003-10-14 Millennium Pharmaceuticals, Inc. Inhibitors of factor Xa
WO2001032628A1 (en) * 1999-11-03 2001-05-10 Bristol-Myers Squibb Pharma Company Cyano compounds as factor xa inhibitors
WO2002000651A2 (en) * 2000-06-27 2002-01-03 Bristol-Myers Squibb Pharma Company Factor xa inhibitors

Also Published As

Publication number Publication date
TW200503694A (en) 2005-02-01
JP4608495B2 (ja) 2011-01-12
ATE394396T1 (de) 2008-05-15
EP1628971B1 (en) 2008-05-07
WO2004101555A1 (en) 2004-11-25
EP1628971A1 (en) 2006-03-01
IL171843A (en) 2010-12-30
EP1479679A1 (en) 2004-11-24
AU2004238498A1 (en) 2004-11-25
AU2004238498B2 (en) 2010-07-22
JP2006528941A (ja) 2006-12-28
CA2526082A1 (en) 2004-11-25
DE602004013577D1 (de) 2008-06-19
MXPA05012058A (es) 2006-06-23
PE20050154A1 (es) 2005-04-29
BRPI0410763A (pt) 2006-08-01

Similar Documents

Publication Publication Date Title
US7429581B2 (en) Pyrazole-derivatives as factor Xa inhibitors
EP1628972B1 (en) INDAZOLE-DERIVATIVES AS FACTOR Xa INHIBITORS
US7223780B2 (en) Triazole-derivatives as blood clotting enzyme factor Xa inhibitors
WO2004056815A1 (en) PYRAZOLE-DERIVATIVES AS FACTOR Xa INHIBITORS
US20070049573A1 (en) Pyrrole-Derivatives as Factor Xa Inhibitors
CA2526082C (en) Triazole-derivatives as factor xa inhibitors
EP1571154A1 (en) Beta-aminoacid-derivatives as factor Xa inhibitors
US7741341B2 (en) Benzimidazole-derivatives as factor Xa inhibitors
CA2507624A1 (en) Imidazole-derivatives as factor xa inhibitors
EP1479676A1 (en) Benzimidazole-derivatives as factor xa inhibitors
EP1479678A1 (en) Pyrazole-derivatives as factor xa inhibitors
OA13169A (en) Azaindole-derivatives as factor Xa inhibitors.
CA2609288C (en) Heteroaryl-carboxylic acid (sulfamoyl alkyl) amide - derivatives as factor xa inhibitors
EP1479674A1 (en) Imidiazole-derivatives as factor xa inhibitors

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20160505